Variable | Sustained remission (n = 39) | No sustained remission (n = 83) | P value |
---|---|---|---|
Female, n (%) | 34 (87.2) | 65 (78.3) | 0.24 |
Age, years | 50.3 ± 18.8 (53.0) | 60.1 ± 14.0 (62.0) | 0.0067 |
Weight, kg | 52.9 ± 9.1 (51.5) | 54.2 ± 11.2 (53.0) | 0.70 |
Disease duration, years | 4.9 ± 7.2 (1.8) | 9.8 ± 10.0 (7.0) | 0.0061 |
DAS28-ESR at baseline | 4.12 ± 0.88 (4.09) | 4.68 ± 1.37 (4.48) | 0.014 |
RF-positive, n (%) | 25 (64.1) | 59 (71.1) | 0.44 |
ACPA-positive, n (%) | 26 (72.2) | 51 (73.9) | 0.85 |
Presence of bone erosion, n (%) | 26 (68.4) | 63 (77.8) | 0.27 |
HAQ-DI at baseline | 0.63 ± 0.69 (0.38) | 1.16 ± 0.82 (1.00) | 0.0009 |
MTX use, n (%) | 38 (97.4) | 63 (75.9) | 0.0033 |
Oral steroid use, n (%) | 6 (15.4) | 30 (36.1) | 0.019 |
Prior use of biologics, n (%) | 3 (7.7) | 32 (38.6) | 0.0004 |